Osi Pharmaceuticals Inc Watch

from 10-K/A 2 pages Compensatory Arrangements for Executive Officers

from 8-K 5 pages (I) You Will Be Entitled to a Lump Sum Cash Payment as Soon as Practicable but in No Event Later Than 10 Days After the Date on Which You Have Incurred a Severance (The “Severance Date”) Equal to (A) One Times (1x) Your Annual Base Salary (Immediately Prior to the Change in Control or Immediately Prior to Your Severance Date, Whichever Is Higher) Plus (B) a Pro-Rated Bonus in Respect of the Fiscal Year in Which the Change of Control Occurs for the Period Up to and Including the Severance Date, Based on 100% of Target (As Defined in Osip’s Compensation Program) Plus (C) Any Accrued but Previously Unpaid Annual Base Salary and Any Accrued Vacation Pay Through the Severance Date; (II) for a Period of 12 Months Following the Severance Date, Osip Will, at Its Sole Expense, Provide to You and Your Eligible Dependents Group Medical and Dental Benefits Substantially Similar to the Benefits Provided to You Under the Osip Group Medical and Dental Plans in Which You Were Eligible to Participate Immediately Prior to the Severance Date Or, if More Favorable to You, Immediately Prior to the Change in Control. the Coverage Period for Purposes of the Group Health Continuation Requirements of Section 4980b of the Internal Revenue Code (Commonly Referred to as the Cobra Continuation Period) Will Be Treated as Commencing on the Date Immediately Following the 12-Month Period Referred in This Section; And

from 8-K 2 pages A Promotion to Vice-President of Clinical Research – Oncology, Initially Reporting to Dr. Karsten Witt, Interim Head of Oncology Development. the Position Will Be at Grade 10 and Carries an Annual Bonus Target of 30% Base Salary; · Your Annual Salary Will Be Increased to $330,000, Less Taxes. This Comprises the 5% Commitment Increase Noted in the Letter You Received in July and an Additional Promotional Increase; · Membership of the Osi Executive Management Committee; · a Commitment Bonus Equal to 6 Months Salary and a Relocation Package as Previously Communicated to You in the July Letter; And,

from 8-K 4 pages For Purposes of This Letter Agreement, the Terms Change in Control, Cause and Good Reason (And the Defined Terms Included in Such Definitions) Shall Have the Meaning Set Forth on Appendix a Hereto. in the Event That Any of the Payments Referenced Herein Must Be Delayed So as to Avoid the Imposition of Additional Taxes Upon You Pursuant to the Operation of Section 409a of the Internal Revenue Code of 1986, as Amended, Such Payments Shall Be Delayed Until the Date Which Is Six Months and One Day Following a Severance. David, I Congratulate You on This Achievement and Trust You Will Meet the Challenges of Your New Position With Great Success. if You Are in Agreement With This Letter, Please Sign Both Copies of This Letter and Return One Copy to Amy Sheehan in the Enclosed Envelope. One Copy Is for Your Records

from 8-K 2 pages Revised – March 24, 2006 March 23, 2006 Strictly Private & Confidential 1) Your Start Date Will Be on or Around Monday, April 24, 2006. Please Indicate on the Second Page of This Offer Your Intended Start Date

from 8-K 4 pages In the Event That There Is a “Change in Control” of Osi Pharmaceuticals, Inc. (“Osip”) and Within 12 Months Following a Change in Control Either (A) Your Employment Is Terminated Without “Cause” or (B) You Terminate Your Employment With “Good Reason” (Terminations Following a Change in Control Described in Clause (A) or (B) Being Referred to Herein as a “Severance”),

from 8-K 15 pages Prosidion Limited and Osi Pharmaceuticals (Uk) Limited Change in Control Severance Plan

from 8-K 16 pages Osi Pharmaceuticals, Inc. Change in Control Severance Plan

from 10-K 2 pages Compensatory Arrangements for Executive Officers

from 10-K 2 pages Compensatory Arrangements for Non-Employee Directors

from 10-K 10 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Asterisks Denote Omissions. Prosidion Limited Statement of Particulars of Employment

from 10-K 67 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Asterisks Denote Omissions. Aia ® Document A141tm — 2004 Standard Form of Agreement Between Owner and Design-Builder

from 10-K 4 pages Osi Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan Restricted Stock Unit Agreement

from 10-K 4 pages Osi Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan Restricted Stock Unit Agreement

from 10-K 3 pages Osi Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan Restricted Stock Unit Agreement

from 10-K 3 pages Osi Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan Restricted Stock Unit Agreement

from 10-K 5 pages Osi Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan Non-Qualified Stock Option

from 10-K 5 pages Osi Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan Non-Qualified Stock Option

from 10-K 5 pages Osi Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan Non-Qualified Stock Option Agreement

from 10-K 5 pages Osi Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan Non-Qualified Stock Option Agreement